Diamyd Medical has announced that 90% of the total 320 children enlisted to participate in its European Phase III study have received the diabetes vaccine Diamyd.
Diamyd is conducting a clinical trial for the new vaccine candidate in adolescents with type 1 diabetes, across nine countries in Europe and also the US.
The purpose of the study is to investigate whether the Diamyd vaccine can delay or stop the breakdown of beta cells in the pancreas, preserving the body’s ability of newly diagnosed patients to control their own blood sugar levels.
Diamyd Medical president and CEO Elisabeth Lindner said that the company was close to its first important milestone.
“The results will be analysed during spring 2011, when all patients have participated in the study for 15 months,” Lindner said.